Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
© 2023. Springer Nature Limited..
In preclinical studies rapamycin was found to target neuroinflammation, by expanding regulatory T cells, and affecting autophagy, two pillars of amyotrophic lateral sclerosis (ALS) pathogenesis. Herein we report a multicenter, randomized, double-blind trial, in 63 ALS patients who were randomly assigned in a 1:1:1 ratio to receive rapamycin 2 mg/m2/day,1 mg/m2/day or placebo (EUDRACT 2016-002399-28; NCT03359538). The primary outcome, the number of patients exhibiting an increase >30% in regulatory T cells from baseline to treatment end, was not attained. Secondary outcomes were changes from baseline of T, B, NK cell subpopulations, inflammasome mRNA expression and activation status, S6-ribosomal protein phosphorylation, neurofilaments; clinical outcome measures of disease progression; survival; safety and quality of life. Of the secondary outcomes, rapamycin decreased mRNA relative expression of the pro-inflammatory cytokine IL-18, reduced plasmatic IL-18 protein, and increased the percentage of classical monocytes and memory switched B cells, although no corrections were applied for multiple tests. In conclusion, we show that rapamycin treatment is well tolerated and provides reassuring safety findings in ALS patients, but further trials are necessary to understand the biological and clinical effects of this drug in ALS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nature communications - 14(2023), 1 vom: 17. Aug., Seite 4970 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mandrioli, Jessica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Interleukin-18 |
|---|
| Anmerkungen: |
Date Completed 21.08.2023 Date Revised 19.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-023-40734-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360908357 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360908357 | ||
| 003 | DE-627 | ||
| 005 | 20231226084022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-023-40734-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360908357 | ||
| 035 | |a (NLM)37591957 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mandrioli, Jessica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2023 | ||
| 500 | |a Date Revised 19.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Springer Nature Limited. | ||
| 520 | |a In preclinical studies rapamycin was found to target neuroinflammation, by expanding regulatory T cells, and affecting autophagy, two pillars of amyotrophic lateral sclerosis (ALS) pathogenesis. Herein we report a multicenter, randomized, double-blind trial, in 63 ALS patients who were randomly assigned in a 1:1:1 ratio to receive rapamycin 2 mg/m2/day,1 mg/m2/day or placebo (EUDRACT 2016-002399-28; NCT03359538). The primary outcome, the number of patients exhibiting an increase >30% in regulatory T cells from baseline to treatment end, was not attained. Secondary outcomes were changes from baseline of T, B, NK cell subpopulations, inflammasome mRNA expression and activation status, S6-ribosomal protein phosphorylation, neurofilaments; clinical outcome measures of disease progression; survival; safety and quality of life. Of the secondary outcomes, rapamycin decreased mRNA relative expression of the pro-inflammatory cytokine IL-18, reduced plasmatic IL-18 protein, and increased the percentage of classical monocytes and memory switched B cells, although no corrections were applied for multiple tests. In conclusion, we show that rapamycin treatment is well tolerated and provides reassuring safety findings in ALS patients, but further trials are necessary to understand the biological and clinical effects of this drug in ALS | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Interleukin-18 |2 NLM | |
| 650 | 7 | |a Ribosomal Proteins |2 NLM | |
| 700 | 1 | |a D'Amico, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Zucchi, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a De Biasi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Banchelli, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Martinelli, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Simonini, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Lo Tartaro, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Vicini, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Fini, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Gianferrari, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Pinti, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Lunetta, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Gerardi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Tarlarini, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzini, Letizia |e verfasserin |4 aut | |
| 700 | 1 | |a De Marchi, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Scognamiglio, Ada |e verfasserin |4 aut | |
| 700 | 1 | |a Sorarù, Gianni |e verfasserin |4 aut | |
| 700 | 1 | |a Fortuna, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Lauria, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Bella, Eleonora Dalla |e verfasserin |4 aut | |
| 700 | 1 | |a Caponnetto, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Meo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Chio, Adriano |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cossarizza, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 17. Aug., Seite 4970 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:17 |g month:08 |g pages:4970 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-40734-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 17 |c 08 |h 4970 | ||